NASDAQ · BBIO
BridgeBio Pharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for BBIO has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.53 | $0.13 | $-0.87 | 7 |
| Mar 2027 | $-0.41 | $-0.18 | $-0.63 | 5 |
| Jun 2027 | $-0.19 | $0.19 | $-0.46 | 5 |
| Sep 2027 | $0.02 | $0.49 | $-0.30 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · Zacks · RTTNews- The Motley Fool · 5 h agoBridgeBio (BBIO) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 29, 10:21 PM EDTBridgeBio Pharma, Inc. Reports Third Quarter 2026 Financial Results and Corporate UpdatesBridgeBio Pharma, Inc. reported its financial results for the third quarter ended September 30, 2026, with total revenues of $353.2 million, primarily comprised of $253.2 million of U.S. Attruby net product revenue, which was up approximately $31 million sequentially and $145 mil
- Zacks · Oct 29, 4:30 PM EDTBridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Oct 29, 4:10 PM EDTBridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesBridgeBio Pharma (BBIO) delivered earnings and revenue surprises of +30.00% and +19.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Zacks · Oct 21, 8:06 AM EDTThe Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsBridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
- Zacks · Oct 20, 9:30 AM EDT4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowBBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
- RTTNews · Oct 12, 3:06 AM EDTBridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism(RTTNews) – On Sunday, BridgeBio Pharma, Inc. (BBIO), a biopharmaceutical company, presented additional Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1. The findings were presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meet
- RTTNews · Oct 12, 2:51 AM EDTBridgeBio Highlights Attruby Data Showing Lower Hospitalization Risk In ATTR-CM At HFSA 2026(RTTNews) – BridgeBio Pharma, Inc. (BBIO) announced the presentation of new real-world and Phase 3 data on acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.
- RTTNews · Oct 12, 1:19 AM EDTBridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis(RTTNews) – BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- BNK Invest · Oct 8, 4:41 PM EDTBridgeBio Pharma Becomes Oversold (BBIO)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for BridgeBio Pharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.